Behandlung früher und intermediärer Stadien des Hodgkin-Lymphoms

Abramson JS, Arnason JE, Lacasce AS et al (2019) Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 134:606–613

Aleman BM, Van Den Belt-Dusebout AW, De Bruin ML et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878–1886

Aleman BM, Van Den Belt-Dusebout AW, Klokman WJ et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439

Allen PB, Savas H, Evens AM et al (2021) Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 137:1318–1326

Andre MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1794

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten, Kurzversion 3.1, 2022; AWMF Registernummer: 018/029 OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/hodgkin-lymphom/. Zugegriffen: 23. März 2022

Behringer K, Goergen H, Hitz F et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418–1427

Boll B, Goergen H, Arndt N et al (2013) Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 31:4431–4437

Boll B, Gorgen H, Fuchs M et al (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31:1522–1529

Borchmann P, Plutschow A, Kobe C et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223–234

Brockelmann PJ, Goergen H, Keller U et al (2020) Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol 6:872–880

Cheson BD, Bartlett NL, Laplant B et al (2020) Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol 7:e808–e815

Eichenauer DA, Aleman BMP, Andre M et al (2018) Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv19–iv29

Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495–3502

Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652

Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608

Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927

Forero-Torres A, Holkova B, Goldschmidt J et al (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126:2798–2804

Fuchs M, Goergen H, Kobe C et al (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol. https://doi.org/10.1200/JCO.19.00964

Gillessen S, Plutschow A, Fuchs M et al (2021) Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 8:e278–e288

Hay AE, Klimm B, Chen BE et al (2012) Treatment of stage I–II A non-bulky Hodgkin’s lymphoma (HL): an individual patient-data comparison of German Hodgkin study group (GHSG) HD10 and HD11 combined-modality therapy (CMT) and NCIC clinical trials group (NCIC CTG) HD.6 ABVD alone. ASH Annu Meet Abstr 120:548

Kumar A, Casulo C, Advani RH et al (2021) Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 39:2257–2265

Noordijk EM, Carde P, Dupouy N et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135

Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607

Sasse S, Brockelmann PJ, Goergen H et al (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35:1999–2007

Sobesky S, Mammadova L, Cirillo M et al (2021) In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkins lymphoma and facilitates ultrasensitive residual disease detection. Med 2:1171–1193.e1111

Voltin CA, Mettler J, Van Heek L et al (2021) Early response to first-line anti-PD‑1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial. Clin Cancer Res 27:402–407

Fuchs M, Borchmann P, Greil R, Hitz F, Naumann R, Sasse S, Engert A (2021) Hodgkin Lymphom. Onkopedia